TABLE 3.

Clinical outcomes in patients who showed oligoprogressive disease during ICI therapy and who underwent local ablative therapy

No.	Age	Sex	ICI	Histology	Major driver mutation	BI	Treatment lines	PFS (mo)	Progression sites	LAT	Days to next therapy after LAT	Subsequent therapy
1	60	M	PB	NOS	None	720	1	1.4	Abdominal LN	Ope	33	CBDCA + nabPTX
2	58	M	NV	Sq	None	760	2	3.7	Bone	Rad	28	DTX
3	61	M	NV	Pleo	None	800	2	3.9	Abdominal LN	Ope	(no therapy)	No systemic therapy
4	53	M	PB	Sarco	None	600	3	7.5	Gallbladder	Rad	14	PB beyond PD
5	72	M	NV	Sq	None	0	2	8.2	Abdominal LN	Rad	1	NV beyond PD
6	58	M	NV	LCNEC	None	760	2	12.6	Adrenal gland	Ope	16	NV beyond PD
7	74	M	NV	Ad	None	675	2	14.3	Brain	Rad	10	NV beyond PD
8	78	M	NV	Sq	None	1050	4	14.5	Abdominal LN	Rad	64	NV beyond PD
9	72	M	NV	Sq	None	820	2	15.8	Abdominal LN	Ope	34	NV beyond PD
10	66	F	NV	Ad	EGFR Exon 20 insertion	840	2	22.2	Chest wall LN	Ope	(no therapy)	No systemic therapy

Abbreviations: Ad, adenocarcinoma; BI, Brinkman index; CBDCA, carboplatin; DTX, docetaxel; EGFR, epidermal growth factor receptor; ICI, immune checkpoint inhibitor; LAT, local ablative therapy; LCNEC, large cell neuroendocrine carcinoma; LN, lymph node; nabPTX, nab‐paclitaxel; NOS, not otherwise specified; NV, nivolumab; Ope, operation; PB, pembrolizumab; PD, progressive disease; PFS, progression‐free survival; Pleo, pleomorphic carcinoma; Rad, radiation; Sarco, sarcomatoid carcinoma; Sq, squamous cell carcinoma.